Genelux (GNLX) Company Overview

Profile

Full Name:

Genelux Corporation

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

January 26, 2023

Indexes:

Not included

Description:

Genelux Corporation (GNLX) is a biotechnology company focused on developing innovative cancer therapies. They use a unique approach involving oncolytic viruses, which selectively target and destroy cancer cells while sparing healthy tissue. Their goal is to improve treatment options and outcomes for cancer patients.

Key Details

Price

$4.44

Annual Revenue

$170.00 K(-98.46% YoY)

Annual EPS

-$1.16(-425.12% YoY)

Annual ROE

-145.31%

Beta

1.51

Events Calendar

Earnings

Next earnings date:

Apr 1, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Apr 1, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 15, 24 HC Wainwright & Co.
Buy
Oct 29, 24 Guggenheim
Buy
Aug 27, 24 Roth MKM
Buy
Aug 15, 24 HC Wainwright & Co.
Buy
Jun 3, 24 Benchmark
Speculative Buy
May 31, 24 Benchmark
Speculative Buy
May 13, 24 HC Wainwright & Co.
Buy
Apr 3, 24 Benchmark
Speculative Buy
Apr 2, 24 HC Wainwright & Co.
Buy
Nov 27, 23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Genelux Corporation Announces New Chief Financial Officer
Genelux Corporation Announces New Chief Financial Officer
Genelux Corporation Announces New Chief Financial Officer
GNLX
globenewswire.comFebruary 3, 2025

WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025.

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
GNLX
globenewswire.comDecember 13, 2024

WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024
Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024
Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024
GNLX
globenewswire.comJuly 30, 2024

WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG's Virtual Biotechnology Conference 2024.

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
GNLX
globenewswire.comMay 24, 2024

WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants to purchase 6,875,000 shares of its common stock at a combined offering price of $4.00 per share and accompanying warrant, in each case before underwriting discounts and commissions.

Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
GNLX
Zacks Investment ResearchApril 26, 2024

Genelux Corporation (GNLX) appears to be oversold at the moment, suggesting that the recent selling pressure may have subsided. This, combined with analysts' optimistic outlook on earnings, could potentially signal a turnaround in the stock's performance.

After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)
After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)
After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)
GNLX
Zacks Investment ResearchApril 5, 2024

Genelux Corporation (GNLX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy
All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy
All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy
GNLX
Zacks Investment ResearchApril 4, 2024

Genelux Corporation (GNLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Why Shares of Genelux Climbed This Week
Why Shares of Genelux Climbed This Week
Why Shares of Genelux Climbed This Week
GNLX
The Motley FoolJuly 28, 2023

Genelux recently announced management changes. The company's lead therapy is oncology treatment Olvi-Vec.

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer
Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer
Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer
GNLX
Seeking AlphaJuly 11, 2023

Genelux, an immuno-oncology frontrunner, has secured over $65 million in financing and is conducting successful clinical trials for its primary candidate, Olvi-Vec, a cancer treatment that targets and destroys cancer cells. The company recently raised $18 million through the private placement of 900,000 shares, and its cash runway is projected to extend into Q1 2026, allowing it to pursue its objectives and strategies. Genelux's Olvi-Vec has shown promising results in clinical trials, demonstrating its capacity to penetrate and multiply within distant tumor sites.

Why Shares of Genelux Corporation Jumped This Week
Why Shares of Genelux Corporation Jumped This Week
Why Shares of Genelux Corporation Jumped This Week
GNLX
The Motley FoolJune 1, 2023

Genelux focuses on hard-to-treat cancers. Its lead therapy is Olvi-Vec, which did well in a phase 2 trial to treat ovarian cancer.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Genelux?
  • Does Genelux pay dividends?
  • What sector is Genelux in?
  • What industry is Genelux in?
  • What country is Genelux based in?
  • When did Genelux go public?
  • Is Genelux in the S&P 500?
  • Is Genelux in the NASDAQ 100?
  • Is Genelux in the Dow Jones?
  • When was Genelux's last earnings report?
  • When does Genelux report earnings?
  • Should I buy Genelux stock now?

What is the ticker symbol for Genelux?

The ticker symbol for Genelux is NASDAQ:GNLX

Does Genelux pay dividends?

No, Genelux does not pay dividends

What sector is Genelux in?

Genelux is in the Healthcare sector

What industry is Genelux in?

Genelux is in the Biotechnology industry

What country is Genelux based in?

Genelux is headquartered in United States

When did Genelux go public?

Genelux's initial public offering (IPO) was on January 26, 2023

Is Genelux in the S&P 500?

No, Genelux is not included in the S&P 500 index

Is Genelux in the NASDAQ 100?

No, Genelux is not included in the NASDAQ 100 index

Is Genelux in the Dow Jones?

No, Genelux is not included in the Dow Jones index

When was Genelux's last earnings report?

Genelux's most recent earnings report was on Nov 14, 2024

When does Genelux report earnings?

The next expected earnings date for Genelux is Apr 1, 2025

Should I buy Genelux stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions